We are live on
!
Find out more
Galectin Therapeutics
GALT
GALT
93 hedge funds and large institutions have $12.7M invested in Galectin Therapeutics in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0.48% more ownership
Funds ownership: 16.2% → 16.67% (+0.48%)
2% less capital invested
Capital invested by funds: $13M → $12.7M (-$284K)
1% less funds holding
Funds holding: 94 → 93 (-1)
40% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 30
71% less call options, than puts
Call options by funds: $757K | Put options by funds: $2.57M
Holders
93
Holders Change
-1
Holders Change %
-1.06%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
18
Reduced
30
Closed
12
Calls
$757K
Puts
$2.57M
Net Calls
-$1.81M
Net Calls Change
-$72K
Top Buyers
Top Sellers
| 1 |
BlackRock
New York
|
-$332K |
| 2 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$149K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$104K |
| 4 |
Barclays
London,
United Kingdom
|
-$63.6K |
| 5 |
Morgan Stanley
New York
|
-$63.1K |
